Abstracts

Citation

Elizabeth (Betsy) Smith, M.D. Ongoing nucleoside safety review of HIV-exposed children in US studies.

Citation

Carolyn Bolton, Pearl Samson, Edmund Capparelli, Mutsawashe Bwakura-Dangarembizi, Patrick Jean-Phillippe, Nahida Chakhtoura, Alex Benns, Bonnie Zimmer, Chivon Jackson, Ellen Chadwick for the IMPAACT P1070 team. Optimal use of Efavirenz in HIV+/ TB+ Co-infected Children aged 3 to = 24 months. Presented at: CROI 2016; 2016 Feb 25.

Citation

K Patel, B Simth, IJ Collins, R BGoodall, E Abrams, A Sohn, T Mohamed, R Van Dyke, P Rojo, K Wools-Kaloustian, J Pinto, A Edmonds, I Marete, M Paul, H Nuwaqaba-Biribonwoha, V Leroy, M-A Davies, R Vreeman, CIPHER Cohort Collaboration Duration of Second-line Proi. Outcomes of second-line antiretroviral therapy (ART) in HIV-infected children: a CIPHER cohort collaboration global analysis. Presented at: IAS 2018; 2018 Jul 25.

Citation

T Meyers, P Krogstad, P Samson, E Acosta, J Moye, E Townley, S Bradford, L Marillo, L Hovind, T Sise, H Teppler, S Dittmer, L Fairlie, A Hesseling, M Cotton. P1101: Phase I/II Study of a Raltegravir Containing Regimen in HIV-TB Cotreated Children. Presented at: CROI 2018; 2018 Mar 05.

Citation

P Krogstad, P Samson, T Meyers, E Acosta, J Moye, E Townley, S Bradford, L Marillo, K Denson, L Hovind, T Sise, H Teppler, S Dittmer, L Fairlie, A Hesseling, M Cotton. P1101: Phase I/II Study of Raltegravir-Containing Regimen in HIV and TB Co-Treated Children Aged 6-12 Years. Presented at: 10th International Workshop on HIV Pediatrics; 2018 Jul 20.

Citation

Yvonne J. Bryson, M.D., Ruth E. Dickover, Ph.D., Alice M. Stek, M.D., Mark Mirochnick, M.D., James D. Connor, M.D., Lynne M. Mofenson, M.D., F.A.A.P., Heather D. Watts, M.D., Sharon Huang, M.S., Michael Hughes, Ph.D., B. Cunnington, Lynette Purdue, Pharm.D., Diane W. Wara, M.D., Yetemegnu Asfaw, B.S., Elizabeth (Betsy) Smith, M.D. PACTG 353: Combined Treatment with HAART (NFV/3TC/ZDV) Increases Thymic Output in HIV Infected Pregnant Women.

Citation

Mobeen H. Rathore, M.D., Ross E. McKinney, Jr., M.D., ChengCheng Hu, Ph.D., Paula Britto, M.S., Elizabeth (Betsy) Smith, M.D., Leslie Serchuck, M.D., Linda Draper (Marillo), B.A., Maria-Arantxa Horga, M.D., Gregory E. Chittick, B.S., Adriana Weinberg, M.D. PACTG protocol 1021: a phase I/II study of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Age related Pharmacokinetics of Efavirenz Solutions. Presented at: 15th Conference on Retroviruses & Opportunistic Infections.

Citation

Brenda Asiimwe-Kateera, Kenneth Kintu, Sheryl L. Zwerski, M.S.N, Molly Swenson, Molly Swenson, Lynda Emel, John ( Jack ) Moye, Jr., M.D., Mary Glenn Fowler, M.D., M.P.H., Philippa Musoke, MB ChB, Lynn Baglyos, M.S.N, Laura A. Guay, M.D. Participant Retention and Safety of ALVAC-HIV vCP1521 in Infants Born to HIV-1 Infected Women in Uganda (HPTN 027). Presented at: Annual International Meeting of the Institute of Human Virol.

Citation

M Gockenbach, M Grimstein, Y Yang, J Momper, M Mirochnick, T Johnson, H Sachs for the Antiretrovirals in Pregnancy PBPK Modeling Group. PBPK MODELING OF RILPIVIRINE DURING PREGNANCY. Presented at: American Society for Clinical Pharmacology & Therapeutics.

Citation

M Gockenbach, M Grimstein, Y Wang, J Momper, M Mirochnick, E Capparelli, K Struble, J Wang, T Johnson, H Sachs for the Antiretrovirals in Pregnancy PBPK Modeling Group. PBPK MODELING OF RILPIVIRINE DURING PREGNANCY. Presented at: 20th International Workshop on Clinical Pharmacology of HIV Hepatitis & Other Antiviral Drugs Conference.